Mark G. Kris, MD | Authors




Commentary (Hurria/Kris): Treatment of Non–Small-Cell Lung Cancer in Older Persons

January 01, 2003

Drs. Basche and Kelly presentan excellent comprehensivereview of the treatment ofnon–small-cell lung cancer in olderpersons. Articles such as this, whichfocus on the older patient, are of paramountimportance for several reasons.First, cancer is a disease ofaging, with an 11-fold increased incidenceand a 16-fold increase in cancer-related mortality among patientsover age 65 compared to those under65.[1] Second, the population is aging,and in the year 2030, approximately22% will be over 65.[1] Third,data on older cancer patients are limitedsecondary to an underrepresentationof this population in clinicaltrials.[2,3] Based on these facts, acomprehensive review of the availabledata is important, especially toguide future research.

Optimal Use of Antiemetics in the Outpatient Setting

October 01, 2002

In his article, Dr. Grunberg charts the history of our understanding of chemotherapy-induced nausea and vomiting, and the discovery and development of drugs for its prevention. He places appropriate emphasis on the serotonin (5-HT3) antagonists-notably, ondansetron, granisetron, and dolasetron-which have revolutionized the field over the past decade.

Docetaxel: Emerging Options in the Management of Non-Small-Cell Lung Cancer

July 01, 1997

In the United States, an estimated 178,000 new cases of lung cancer will occur in 1997, accounting for 13% of cancer diagnoses and 29% of all cancer deaths.[1] The majority of these deaths will be due to metastatic non-small-cell lung cancer. Cisplatin (Platinol), vindesine (Eldisine), vinblastine, ifosfamide (Ifex), and mitomycin (Mutamycin) demonstrate response rates of 15% or higher in previously untreated patients (Table 1)